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Abstract
Background: Members of the urokinase-type plasminogen activator (uPA) system are up-regulated in various solid
malignant tumors. High antigen levels of uPA, its inhibitor PAI-1 and its receptor uPAR have recently been shown
to be associated with poor prognosis in soft-tissue sarcoma (STS) patients. However, the mRNA expression of uPA
system components has not yet been comprehensively investigated in STS patients.
Methods: The mRNA expression level of uPA, PAI-1, uPAR and an uPAR splice variant, uPAR-del4/5, was analyzed
in tumor tissue from 78 STS patients by quantitative PCR.
Results: Elevated mRNA expression levels of PAI-1 and uPAR-del4/5 were significantly associated with clinical
parameters such as histological subtype (P = 0.037 and P < 0.001, respectively) and higher tumor grade (P = 0.017
and P = 0.003, respectively). In addition, high uPAR-del4/5 mRNA values were significantly related to higher tumor
stage of STS patients (P = 0.031). On the other hand, mRNA expression of uPA system components was not
significantly associated with patients’ survival. However, in STS patients with complete tumor resection (R0), high
PAI-1 and uPAR-del4/5 mRNA levels were associated with a distinctly increased risk of tumor-related death (RR =
6.55, P = 0.054 and RR = 6.00, P = 0.088, respectively). Strikingly, R0 patients with both high PAI-1 and uPAR-del4/5
mRNA expression levels showed a significant, 19-fold increased risk of tumor-related death (P = 0.044) compared to
the low expression group.
Conclusion: Our results suggest that PAI-1 and uPAR-del4/5 mRNA levels may add prognostic information in STS
patients with R0 status and distinguish a subgroup of R0 patients with low PAI-1 and/or low uPAR-del4/5 values
who have a better outcome compared to patients with high marker levels.
Background
Soft-tissue sarcomas (STS) are malignant mesenchymal
neoplasias with an incidence of about 1% among all
human malignancies [1]. STS enlarge leading to the
appearance of a pseudo capsule composed of an inner
compression zone and an outer reactive zone at forma-
tion of fingers, which give rise to satellite lesions several
centimeters away from the primary tumor [2]. The
major clinical problems in the treatment of STS are the
propensity of the tumor to recur locally, and the fact
that many patients without obvious clinical metastases
harbor occult micro-metastases that become clinically
evident. Lymph node metastases are rare in STS patients
[3,4]. Despite adequate local control of the primary
tumor, about 50% of sarcoma patients will succumb to
distant metastatic disease [5].
The urokinase plasminogen activator (uPA) system
has been shown to play a major role in the pericellular
network of interacting proteolytic systems that are able
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tate tumor invasion and metastasis [6,7]. Furthermore,
components of the uPA system have been implicated in
proliferation, migration and adhesion of tumor cells as
well as in tumor angiogenesis [8,9]. Components of the
uPA system, which consists of the serine protease uPA,
its receptor uPAR and its principal inhibitor PAI-1 are
prognostic factors in different types of cancer. High
antigen levels of uPA and/or PAI-1 protein in tumor tis-
sue extracts are strong predictors of poor prognosis in
patients afflicted with different types of solid malignant
tumors including sarcomas [10,11]. High uPAR levels
are also associated with poor prognosis in various can-
cer types, however, the prognostic impact of uPAR
expression is not as pronounced as that of uPA and
PAI-1 [12,13]. In contrast, the expression of a mRNA
splice variant of wild-type uPAR (uPAR-wt) lacking
exons 4 and 5 (uPAR-del4/5) has been demonstrated to
be a highly sensitive, independent prognostic marker in
breast cancer patients [14-16].
Whereas wild-type uPAR consists of three structurally
homologous domains, in the uPAR-del4/5 variant the
complete domain II of uPAR is deleted, and the uPAR-
del4/5 protein does not interact with either of its ligands
uPA or vitronectin [17]. However, in breast cancer cells
the overexpression of the uPAR-del4/5 protein pro-
foundly affects the in vitro invasion capacity of cells
through a Matrigel matrix, the adhesion to extracellular
matrix proteins and also lung colonization in an in vivo
metastasis model. These observations strongly suggest
that uPAR-del4/5 displays biological activity modulating
tumor biological relevant processes [17].
In sarcomas, high expression of uPA and uPAR anti-
gen as detected by immunohistochemistry has been
reported to be an independent prognostic factor for
metastasis-free survival and overall survival in chondro-
sarcoma patients [18]. In soft-tissue sarcomas, increased
uPA protein levels in tumor tissue were found to signifi-
cantly correlate with local recurrence and metastasis in
a cohort of 69 STS patients [19]. We recently reported a
highly significant correlation between high antigen levels
of uPA, PAI-1 or uPAR in tumor tissue, and of soluble
uPAR in serum, with poor outcome of STS patients
[20]. However, only one report has investigated the
mRNA expression of components of the uPA system in
tumor tissue from soft-tissue sarcoma patients [21]. In
this study, which included 38 STS patients, significantly
higher uPA, PAI-1 and uPAR mRNA expression levels
were observed in tumor tissue compared to paired adja-
cent normal tissue. Additionally, PAI-1 mRNA expres-
sion was found to be 6-fold higher in metastatic tumors
than in non-metastatic tumors [21].
In the present study, we determined the mRNA
expression levels of uPA, PAI-1 and uPAR in a cohort
of 78 adult STS patients and analyzed their relationship
with prognostically relevant clinical and histomorpholo-
gical parameters and disease-associated survival.
Furthermore, the impact of mRNA expression of uPA
system components on disease-associated survival was
evaluated in clinically relevant subgroups of STS
patients with complete (R0) or non-radical (R1) tumor
resection.
Methods
Patients and tumor material
For the present study, tumor tissue samples of 78 adult
patients with histologically verified soft-tissue sarcomas
that have been described in previous studies were used
[20,22]. The study adhered to national regulations on
ethical issues and was approved by the Ethics Commit-
tee from the Medical Faculty of the Martin-Luther-Uni-
versity Halle-Wittenberg, Germany. All patients gave
written informed consent (Institute of Pathology, Uni-
versity of Halle-Wittenberg, Germany and Department
of Surgery 1, University of Leipzig, Germany). The med-
ian age of the patients at surgery was 59 years (range
22-83 years). The median follow-up time of the patients
was 42 months (range 2 to 146 months after primary
tumor resection). During that time, 30 patients experi-
enced a locoregional recurrence, seven developed a dis-
tant metastasis and 42 of the patients have died. The
tumors were staged according to the UICC system. All
of the tumor samples were collected before radio- or
chemotherapy. Relevant data on the clinical and histo-
morphological parameters of the STS patients are
shown in Table 1 and in Additional file 1 .
Quantification of uPA, PAI-1, uPAR-wt and uPAR-del4/5
mRNA by real-time PCR
Tissue processing, isolation of total RNA, cDNA synth-
esis, and evaluation of the quantity and quality of the
isolated RNA were performed as described [22]. Among
the 78 STS patients, the mRNA expression in tumor tis-
sue could be investigated in all cases for uPA and PAI-1
expression, in 77 cases for expression of wild-type uPAR
(uPAR-wt) and in 76 cases for expression of the uPAR
splice variant uPAR-del4/5.
For quantification of uPA, PAI-1, uPAR-wt and uPAR-
del4/5 mRNA, gene-specific hybridization probes and
highly sensitive RT-PCR assays (LC FastStart DNA Mas-
ter Hybridization Probes, Roche Diagnostics, Mannheim,
Germany) applying LightCycler technology (Light Cycler
1.0; Software Version 3.5, Roche) were used as pre-
viously described [14,23]. Briefly, the PCR assays were
performed using 2 μl of a 1:10 dilution of the respective
cDNA products. Primer sequences, concentration of pri-
m e r sa n dp r o b e sa sw e l la sP C Rc o n d i t i o n sf o ra m p l i f i -
cation are shown in Additional file 2. All HPLC-purified
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many). Five-log-range calibration curves were generated
for each PCR run using eight glass capillaries coated with
defined numbers of linearized plasmid molecules (10
1 -
10
6 molecules), carrying either the uPA, the PAI-1 or the
uPAR (wild-type or -del4/5) cDNA (Roboscreen, Leipzig,
Germany). All measurements were performed using ali-
quots of the same cDNA dilutions within short time
intervals to ensure comparable conditions. The cDNA
samples were quantified at least in duplicate in indepen-
dent PCR runs for the appropriate marker transcripts.
The mean values of all measurements were used for
further calculations. The levels of specific mRNAs were
evaluated relative to the average expression levels of the
medium abundance housekeeping gene hypoxanthine
guanine phosphoribosyltransferase (HPRT) as described
[24]. Relative mRNA expression ratios (amol of appropri-
ate marker per amol HPRT) were used for all further cal-
culations and statistical analyses.
Statistical analysis
The levels of significance between continuous variables
of the biological markers were calculated with Spear-
man’s rank correlation test (rs). The relationship
Table 1 Relationship between clinical and histomorphological parameters, and mRNA levels of tumor biological
markers in tumor tissue of STS patients
Patients’ characteristics No. cases uPA PAI-1 No. cases
a uPAR-wt uPAR-del4/5
low/high low/high low/high low/high
Total 78 77/76
Sex
b P = 0.071 P = 0.111 P = 0.031 P = 0.201
Male 35 21/14 20/15 34/33 20/14 18/15
Female 43 18/25 18/25 43 18/25 20/23
Histological subtype
c, d P = 0.135 P = 0.037 P = 0.044 P < 0.001
LS 18 10/8 9/9 18 13/5 15/3
MFH 17 6/11 8/9 16/15 6/10 7/8
FS 3 1/2 0/3 3 1/2 1/2
RMS 6 4/2 3/3 6 3/3 1/5
LMS 17 6/11 6/11 17 6/11 4/13
NS 7 5/2 5/2 7 5/2 5/2
Syn 10 7/3 8/2 10 4/6 5/5
Tumor grade
c P = 0.149 P = 0.017 P = 0.178 P = 0.003
I 15 7/8 6/9 15 8/7 9/6
II 32 20/12 21/11 32 17/15 19/13
III 31 12/19 12/19 30/29 13/17 10/19
Tumor stage
c P = 0.431 P = 0.111 P = 0.483 P = 0.031
I 13 6/7 5/8 13 7/6 8/5
II 31 19/12 20/11 31 16/15 18/13
III 25 9/16 10/15 24/23 11/13 9/14
IV 9 5/4 4/5 9 4/5 3/6
Complete resection
b P = 0.056 P = 0.304 P = 0.437 P = 0.200
Radical (R0) 52 22/30 24/28 52/51 23/29 24/27
Not radical (R1) 26 17/9 15/11 25 15/10 14/11
Tumor localization
c P = 0.197 P = 0.071 P = 0.098 P = 0.394
Extremities 49 22/27 22/27 48/47 19/29 21/26
Trunk wall 6 4/2 3/3 6 5/1 3/3
Head/neck 2 2/0 2/0 2 2/0 1/1
Abdomen/retroperitoneum 21 11/10 12/9 21 12/9 13/8
Patient follow-up
b P = 0.405 P = 0.645 P = 0.748 P = 0.688
Alive 36 15/21 18/18 36/35 18/18 18/17
Dead 42 24/18 21/21 41 20/21 20/21
aThe number of cases for uPAR-wt and uPAR-del4/5 is 77 and 76, respectively.
bP for Mann-Whitney U test,
cP for Kruskal-Wallis test.
dAbbreviations: LS - liposarcoma, MFH - malignant fibrous histiocytoma, FS - fibrosarcoma, RMS - rhabdomyosarcoma, LMS - leiomyosarcoma, NS - neurogenic
sarcoma, Syn - synovial sarcoma; the median mRNA values of the uPAR system components in the different histological STS subtypes are presented in Additional
file 3.
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and histomorphological parameters was evaluated using
non-parametric Mann-Whitney or Kruskal-Wallis tests.
For survival analyses the disease-associated survival of
STS patients was used as the follow-up end point. The
disease-associated survival was defined as the time from
the day of primary surgery to tumor-related death of the
patients. Statistical analyses of the association between
mRNA expression of uPA system components and prog-
nosis were performed by Kaplan-Meier analyses (log-
rank tests) and using the Cox proportional hazard
regression model. The multivariate Cox regression
model was adjusted for the following known clinical
prognostic factors in STS patients: tumor stage, histolo-
gical subtype, type of tumor resection, and tumor locali-
zation. All calculations were performed using the SPSS
17.0 program (SPSS-Science, Chicago, IL). P-values <
0.05 were considered statistically significant.
Results
Expression of uPA, PAI-1, uPAR-wt and uPAR-del4/5
mRNA and their association with clinical and
histomorphological parameters
The expression of uPA and PAI-1 mRNA was deter-
mined in 78 cases, and the expression of uPAR-wt and
uPAR-del4/5 mRNA was determined in 77 and 76 STS
samples, respectively (Table 1). The normalized mRNA
expression values of uPA, PAI-1, uPAR-wt and uPAR-
del4/5 ranged from 0-16.2 (median 0.23; 25th and 75th
percentile 0.055 and 1.03, respectively), from 0-181.9
(median 0.73; 25th and 75th percentile 0.10 and 3.08,
respectively), from 0-24.1 (median 0.18; 25th and 75th
percentile 0.044 and 1.15, respectively), and from 0-0.29
(median 0.004; 25th and 75th percentile 0.0001 and
0.012, respectively), respectively. For statistical analysis,
the median value was set as the cut-off point to separate
STS patients in groups with low or high tissue mRNA
expression.
First, the correlation between the mRNA expression
levels of the biological markers was analyzed using
Spearman’s rank correlation. In general, all factors dis-
played a strong correlation with each other with rs-
values of approximately 0.80; uPA mRNA values signifi-
cantly correlated with PAI-1 (rs =0 . 8 2 ,P < 0.001), with
uPAR-wt (rs =0 . 8 1 ,P < 0.001) and with uPAR-del4/5
(rs =0 . 7 4 ,P < 0.001) mRNA levels. In addition, signifi-
cant correlations were found between uPAR-wt mRNA
levels and both PAI-1 and uPAR-del4/5 mRNA values
(rs = 0.85, P <0 . 0 0 1 ,a n dr s = 0.82, P < 0.001, respec-
t i v e l y )a sw e l la sb e t w e e nP A I - 1a n du P A R - d e l 4 / 5
mRNA values (rs = 0.78, P < 0.001).
The relationship between the mRNA expression levels
and the clinical and histomorphological parameters of
the STS patients is summarized in Table 1. A significant
association was observed between mRNA expression
levels of PAI-1 (P = 0.037), uPAR-wt (P = 0.044) and
uPAR-del4/5 (P < 0.001) and the histological subtype of
STS patients. High mRNA expression levels of these
three markers (and of uPA) were observed, especially in
leiomyosarcomas. Furthermore, mRNA levels of PAI-1
(P = 0.017) and uPAR-del4/5 (P =0 . 0 0 3 )w e r es i g n i f i -
cantly related to tumor grade, and high uPAR-del4/5
mRNA values were associated with a higher tumor stage
in STS patients (P = 0.031). In contrast, mRNA levels of
uPA did not differ significantly between tumors in rela-
tion to clinical and histomorphological parameters
(Table 1).
Association of uPA, PAI-1, uPAR-wt and uPAR-del4/5
expression with disease-associated survival
The association of clinical and histomorphological para-
meters and tumor biological factors with disease-asso-
ciated survival is presented in Table 2. In univariate Cox
regression hazard analysis, two of the clinical para-
meters, tumor stage and tumor resection status were
significantly related to prognosis, i.e. patients with high
stage tumors or with tumors that were not completely
resected (R1) had, as expected, a higher risk for tumor-
related death (Table 2). No significant association
between uPA, PAI-1, uPAR-wt and uPAR-del4/5 mRNA
values with disease-associated survival of STS patients
was observed in both univariate (Table 2) and multivari-
ate Cox regression analyses (data not shown).
We next performed analyses in the subgroup of STS
patients with complete tumor resection (R0) who were
at lower risk for tumor-related death compared to the
patients whose tumors were not completely resected
(R1, Table 2; [25]). We assessed whether some of the
biological markers might add prognostic information for
patients’ survival in the R0 subgroup of STS patients. In
R0 patients, survival time is inversely significantly corre-
lated with expression of PAI-1 mRNA (rs = -0.337, P =
0.014) and of uPAR-del4/5 mRNA (rs = -0.346, P =
0.013) by bivariate correlation analysis using Spearman’s
Rho test (Additional file 3: A). Furthermore, using linear
regression analysis about a third of patients with lower
expression rates for both markers showed the best survi-
val (Additional file 3: B). Therefore it was implicated to
apply the 33% percentiles as cut-off points for R0
patients according to their mRNA expression levels, i.e.
for PAI-1 (33% percentile: 0.228) and for uPAR-del4/5
mRNA expression (33% percentile: 0.001). Accordingly,
R0 patients (n = 52) with mRNA values in the range of
the 0% to the 33% percentile were allocated to the low
expressing group, and all other patients with mRNA
values above the 33% percentile (>33% to 100%) were
designated as the high expressing group. We found an
association between high PAI-1 and uPAR-del4/5
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related death for R0 patients using multivariate Cox
regression analysis with relative risks (RR) of 6.55 (95%
CI = 1.0-44.5) and 6.00 (95%CI = 0.8-47.1), respectively,
with a trend towards significance (P =0 . 0 5 4a n dP =
0.088, respectively; Table 3). A moderately increased
risk of tumor-related death in R0 patients was also
observed for high uPA and uPAR-wt mRNA values (RR
= 3.53, 95%CI = 0.7-16.8, and RR = 2.66, 95%CI = 0.5-
14.4, respectively). However, this risk was not signifi-
cantly different than for R0 patients expressing low uPA
or uPAR-wt mRNA levels (Table 3).
Finally, we assessed whether a combination of PAI-1
and uPAR-del4/5 mRNA values might improve the
Table 2 Univariate Cox regression analysis for the
association of relevant clinical and histomorphological
parameters, and of uPA, PAI-1, uPAR-wt and uPAR-del4/5
mRNA levels in tumor tissue of STS patients with
disease-associated survival
Factor No. cases
a RR (95% CI)
b P
Histological subtype
c
LS 18 1
MFH/ FS 20 2.35 (0.9-6.2) 0.085
RMS/ LMS 23 2.62 (1.0-6.8) 0.050
NS 7 1.57 (0.4-6.3) 0.522
Syn 10 1.29 (0.4-4.4) 0.686
Tumor stage
I1 3 1
II 31 2.88 (0.6-12.9) 0.165
III 25 9.27 (2.1-40.6) 0.003
IV 9 33.5 (7.0-161.0) <0.001
Complete resection
Radical (R0) 52 1
Not radical (R1) 26 2.59 (1.4-4.8) 0.002
Tumor localization
Extremities 49 1
Trunk wall 6 0.88 (0.2-3.8) 0.858
Head/neck 2 3.79 (0.9-16.7) 0.079
Abdomen/retroperitoneum 21 1.93 (1.0-3.8) 0.057
uPA mRNA
d
Low 39 1
High 39 0.73 (0.4-1.4) 0.319
PAI-1 mRNA
d
Low 39 1
High 39 1.18 (0.6-2.2) 0.609
uPAR-wt mRNA
d
Low 39 1
High 38 1.11 (0.6-2.1) 0.736
uPAR-del4/5 mRNA
d
Low 38 1
High 38 1.06 (0.6-2.0) 0.839
aTotal number of cases: n = 78, the number of cases for uPAR-wt and uPAR-
del4/5 is 77 and 76, respectively.
bRR: hazard ratio (95% confidence interval) of univariate Cox regression
analysis.
cAbbreviations: LS - liposarcoma, MFH - malignant fibrous histiocytoma, FS -
fibrosarcoma, RMS - rhabdomyosarcoma, LMS - leiomyosarcoma, NS -
neurogenic sarcoma, Syn - synovial sarcoma.
dRelative mRNA expression ratio of the respective marker / HPRT
dichotomized in high and low levels by median values.
Table 3 Multivariate Cox regression analysis for the
association of relevant clinical and histomorphological
parameters, and of uPA, PAI-1, uPAR-wt and uPAR-del4/5
mRNA levels with disease-associated survival in the
subgroup of STS patients with complete tumor resection
(R0)
Factor No. cases
a RR (95% CI)
b P
Histological subtype
c
LS 15 1
MFH/ FS 11 0.76 (0.1-8.0) 0.820
RMS/ LMS 15 0.37 (0.1-3.3) 0.381
NS 4 7.79 (0.2-240.1) 0.240
Syn 6 5.30 (0.4-76.4) 0.219
Tumor stage
I1 2 1
II 19 0.80 (0.1-17.2) 0.889
III 16 10.97 (0.7-160.8) 0.080
IV 4 347.3 (13.6-8869.8) <0.001
Tumor localization
Extremities 35 1
Trunk wall 6 1.08 (0.1-8.7) 0.939
Head/neck 2 7.44 (0.5-101.8) 0.133
Abdomen/retroperitoneum 8 2.23 (0.3-18.4) 0.454
uPA mRNA
d, e
Low 17 1
High 35 3.53 (0.7-16.8) 0.114
PAI-1 mRNA
d, e
Low 17 1
High 35 6.55 (1.0-44.5) 0.054
uPAR-wt mRNA
d, e
Low 17 1
High 35 2.66 (0.5-14.4) 0.260
uPAR-del4/5 mRNA
d, e
Low 17 1
High 34 6.00 (0.8-47.1) 0.088
aTotal number of cases: n = 52, the number of cases for uPAR-del4/5 is 51.
bRR: hazard ratio (95% confidence interval) of multivariate Cox regression
analysis.
cAbbreviations: LS - liposarcoma, MFH - malignant fibrous histiocytoma, FS -
fibrosarcoma, RMS - rhabdomyosarcoma, LMS - leiomyosarcoma, NS -
neurogenic sarcoma, Syn - synovial sarcoma.
dRelative mRNA expression ratio of the respective marker / HPRT divided into
groups using the 33% percentile; Low: 0 - 33% percentile; High: > 33% - 100%
percentile.
eFactors were added separately to the base model of relevant clinical
prognostic factors in STS patients including the histological subtype, tumor
stage and tumor localization.
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mRNA expression levels of both PAI-1 and uPAR-del4/
5 were divided into groups with low (0-33% percentile)
versus high (> 33% to 100% percentile) values, respec-
tively. In multivariate Cox regression analysis, we found
that patients with low mRNA values of both factors
were characterized by a much better disease-associated
survival than patients with tumors in which one or both
mRNA values were high (Figure 1). R0 patients with
high PAI-1/uPAR-del4/5 (n = 30) revealed a significant
19-fold increased risk of tumor-related death (RR =
19.1, 95%CI = 1.1-335.3, P = 0.044) compared to R0
patients who showed low PAI-1/uPAR-del4/5 mRNA
expression levels (n = 13). Thus, a pronounced additive
effect on prognosis of R0 patients was identified when
combined PAI-1/uPAR-del4/5 mRNA expression levels
i nt u m o rt i s s u ew e r eu s e d .T h er i s ko ft u m o r - r e l a t e d
death for R0 patients with a low/high mRNA expression
(high PAI-1/low uPAR-del4/5 and low PAI-1/high
uPAR-del4/5) was not significantly different from that
for R0 patients with a low PAI-1/uPAR-del4/5 mRNA
expression in their tumors. We did not observe any sig-
nificant correlation for either group with the disease-
associated survival of all STS patients or for the R1
patients. The combination of other factors did also not
provide any additional prognostic information.
Discussion
The uPA system is one of the best-investigated protease
systems in both physiological and pathological conditions,
including cancer [reviewed in [6,7]]. In clinical studies,
high protein contents of uPA and/or PAI-1 in tumor tis-
sue have been shown to indicate an unfavorable prognosis
in various types of cancer [10,11,26]. For example, the
determination of antigen levels of uPA and PAI-1 in tissue
extracts of primary breast cancer has entered clinical prac-
tice for risk-adapted, individual therapy decisions in
patients with lymph node-negative disease [11,26]. In soft-
tissue sarcoma, however, few studies have analyzed the
protein expression of uPA system components and
Figure 1 Multivariate Cox regression analysis for the association of combined PAI-1/uPAR-del4/5 mRNA values with disease-associated
survival in the subgroup of STS patients with complete tumor resection (R0). For each, the PAI-1 and the uPAR-del4/5 mRNA level, the
33% percentile of the relative expression ratio was used as cut-off point. Group 1 (n = 13), low expression levels of PAI-1/uPAR-del4/5 mRNA;
group 2 (n = 8), one of the mRNA values was either low or high; group 3 (n = 30), high expression levels of PAI-1/uPAR-del4/5 mRNA. R0
patients of group 3 (high expression of PAI-1/uPAR-del4/5 mRNA) showed a 19-fold increased risk of tumor-related death (RR = 19.1, 95%CI =
1.1-335.3, P = 0.044) compared to group 1 with low expression of PAI-1/uPAR-del4/5 mRNA.
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prognosis of STS patients. Choong et al. [19] reported that
increasing uPA protein levels in tumor tissue were asso-
ciated with local recurrence and metastasis in 69 STS
patients. Recently, high protein levels of uPA, PAI-1 and
uPAR in tumor tissue extracts were found to be signifi-
cantly associated with a shortened disease-associated sur-
vival of STS patients; this association was independent of
prognostically relevant clinical parameters [20]. Moreover,
combined values of high uPA, PAI-1 or uPAR tissue levels
with high serum levels of soluble uPAR were highly signifi-
cantly and independently associated with poor disease-
associated survival; these patients showed an approxi-
mately 6-fold increased risk of tumor-related death [20].
Generally, measurements of tumor biological markers
in tissue extracts by ELISA require relatively large
amounts of fresh-frozen tumor material as well as ade-
quate storage capacities for tumor samples. Further-
more, tumor tissue material is more limited when the
cancer is diagnosed at early stages because most tumor
tissue specimens are retrieved from fine needle aspirates
or core biopsies [27]. Thus, alternative, less material-
consuming methods for the quantitative determination
of prognostic factors in tumor tissue such as quantita-
tive PCR are desirable.
In the present study, we analyzed the mRNA expression
levels of uPA system components in a cohort of 78
patients with soft-tissue sarcoma, and high correlations
were found between the mRNA values of uPA, PAI-1,
uPAR-wt and an uPAR splice variant, uPAR-del4/5 (with
rs values greater than 0.70). In agreement with these
results, positive correlations between mRNA values of uPA
system components have been observed in several other
studies [23,28-31]. At the protein level, similar significant
correlations between uPA, PAI-1 and uPAR antigen levels
in tumor tissue have been reported [20,23,30,32,33]. These
findings may not be surprising because various interactions
of the members of the plasminogen activation system may
affect each other or are regulated in a concerted manner in
tumor growth and metastasis.
In contrast, we found only low/moderate correlations
between uPA, PAI-1 and uPAR-wt mRNA expression and
the respective antigen levels in tumor tissue from the STS
patient cohort (rs values ranging from 0.26 to 0.35; data
not shown). Other studies have also indicated that uPA
and/or PAI-1 antigen levels in tumor tissue do not com-
pletely reflect the respective mRNA expression level
[23,28,30,34,35]. This discrepancy could be due to post-
transcriptional regulation processes, which have previously
been reported for components of the uPA system [36].
Although mRNA levels do not completely mirror anti-
gen contents in tumor tissue, a number of studies have
demonstrated that mRNA expression levels of certain
uPA system members are linked with clinical and
histomorphological parameters, and/or prognosis in can-
cer patients. In breast cancer, Witzel et al. [35] have
reported that patients with high PAI-1 mRNA expression
have a reduced 10-year disease-free survival and overall
survival rate, and PAI-1 mRNA expression might reveal
additional clinically relevant information compared to
PAI-1 protein levels. In other studies that have analyzed
PAI-1 mRNA expression in different sets of breast cancer
patients, high PAI-1 mRNA levels were found to be sig-
nificantly associated with shorter metastasis-free or over-
all survival, whereas uPA mRNA levels had no prognostic
relevance [37,38]. However, in a subset of ErbB2-positive
breast cancer patients, Urban et al. [29] have identified
uPA mRNA as the most significant marker associated
with distant metastasis-free survival, whereas PAI-1
mRNA was found to be significantly associated with dis-
tant metastasis-free survival, independent of the ErbB2
status. In addition, high uPA and PAI-1 mRNA levels
were found to be significantly associated with shorter dis-
ease-free survival in primary breast cancer patients, inde-
pendent of hormone receptor or lymph node status [28].
In other tumor types, such as pancreatic and gastric can-
cer, mRNA expression of uPA system components has
also been found to be related to prognosis [31,39-41].
However, the existence of studies in which no relation-
ship was found between uPA, PAI-1 or uPAR mRNA
expression and patients’ survival is notable [30,42].
Other studies have also examined uPA system compo-
nents in soft-tissue sarcomas. In a small cohort of 38 STS
patients, significantly higher PAI-1 mRNA expression
levels, but not uPA or uPAR levels, were observed in
metastatic compared to non-metastatic tumors [21]. In
the present study, uPA, PAI-1 and uPAR-wt mRNA values
did not differ significantly between tumors in relation to
clinical and histomorphological parameters, except for a
significant relationship between high PAI-1 mRNA
expression and tumor grade and between PAI-1 and
uPAR-wt mRNA levels and the histological STS subtype,
which has also been reported by others [21]. Interestingly,
mRNA levels of uPAR-del4/5, an uPAR mRNA splice var-
iant described recently [14], were significantly correlated
with clinical prognostic factors such as histological sub-
type, tumor grade and tumor stage in STS patients. How-
ever, the expression levels of uPAR-del4/5 mRNA, which
has recently been shown to be strongly associated with
prognosis in lymph node-negative breast cancer patients
[16], had no prognostic impact in STS patients. Similarly,
mRNA expression of the other uPA system markers did
not show a significant correlation with disease-associated
survival in the whole cohort of STS patients.
However, when we analyzed the expression pattern of
uPA system markers in the subgroup of STS patients
who underwent radical tumor resection (R0) we observed
a trend towards an association between mRNA
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Page 7 of 9expression and disease-associated survival. Specifically,
elevated mRNA values of uPAR-del4/5 and PAI-1 were
associated with a 6-fold increased risk of tumor-related
death in R0 patients (but not in R1 patients). It is tempt-
ing to speculate that increasing the number of patients in
this subgroup analysis would result in significant associa-
tions between high levels of uPAR-del4/5 or PAI-1
mRNA levels and disease-associated survival. Moreover,
by using combined PAI-1 and uPAR-del4/5 mRNA
expression values, R0-resected patients with high PAI-1/
uPAR-del4/5 mRNA values had a significant, 19-fold
increased risk of tumor-related death compared to R0-
resected patients who displayed low PAI-1/uPAR-del4/5
expression levels. These results suggests that the quanti-
tative determination of PAI-1 and uPAR-del4/5 mRNA
expression levels in R0-resected STS patients provides
additional prognostic information that may allow for
individual, risk-adapted (adjuvant) therapy decisions.
Thus, R0 patients at high risk, as identified by elevated
uPAR-del4/5 and/or PAI-1 mRNA levels, may benefit
from chemotherapy, which would result in the reduction
of tumor progression. In contrast, patients displaying low
mRNA expression of both uPAR-del4/5 and PAI-1 in
tumor tissue could be spared the exposure to
chemotherapy.
Conclusions
In the present study, we analyzed mRNA expression
levels of uPA, PAI-1, uPAR and an uPAR mRNA splice
variant, uPAR-del4/5, in a cohort of 78 adult soft-tissue
sarcoma patients. Our data suggest that mRNA levels of
PAI-1 and uPAR-del4/5 are significantly related to clini-
cal and histomorphological parameters of STS patients
such as histological subtype, tumor grade or tumor
stage. In addition, in STS patients with complete tumor
resection high PAI-1 or uPAR-del4/5 mRNA levels are
associated with a distinctly shortened disease-associated
survival of STS patients. Strikingly, co-detection of a
high mRNA level of uPAR-del4/5 and PAI-1 in tumor
tissue of STS patients with complete tumor resection is
associated with a 19-fold increased risk of tumor-related
death suggesting that both markers can be considered
together for prognostic evaluation and may support
future therapy stratification.
Additional material
Additional file 1: Median mRNA values of the uPAR system
components in the different histological STS subtypes. This file
contains additional information on the mRNA expression pattern in the
seven histological tumor subtypes of the STS patient cohort.
Additional file 2: Sequences of primers and hybridization probes,
primer concentrations and amplification conditions for uPA, PAI-1,
uPAR-wt and uPAR-del4/5 applied in the RT-PCR LightCycler assay.
This file contains additional information regarding the characteristics of
primers and probes (sequence, concentration), and the cycling
conditions of the PCR.
Additional file 3: Association of uPAR-del4/5 and PAI-1 mRNA
expression levels with disease-associated survival in the subgroup
of STS patients without residual tumor mass (R0). This file contains
additional statistical data: A. The bivariate correlation between mRNA
expression of uPAR-del4/5 and PAI-1 with survival time of R0-STS patients
(Spearman’s Rho test), and B. The association of mRNA expression of
uPAR-del4/5 and PAI-1 with survival time of R0-STS patients (Regression
model).
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